{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:49:52Z","timestamp":1787240992957,"version":"build-2736575974"},"reference-count":10,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Islet autoantibody testing provides the basis for assessment of risk of progression to type 1 diabetes. We set out to determine the feasibility and acceptability of dried capillary blood spot\u2013based screening to identify islet autoantibody\u2013positive relatives potentially eligible for inclusion in prevention trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Dried blood spot (DBS) and venous samples were collected from 229 relatives participating in the TrialNet Pathway to Prevention Study. Both samples were tested for glutamic acid decarboxylase, islet antigen 2, and zinc transporter 8 autoantibodies, and venous samples were additionally tested for insulin autoantibodies and islet cell antibodies. We defined multiple autoantibody positive as two or more autoantibodies in venous serum and DBS screen positive if one or more autoantibodies were detected. Participant questionnaires compared the sample collection methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of 44 relatives who were multiple autoantibody positive in venous samples, 42 (95.5%) were DBS screen positive, and DBS accurately detected 145 of 147 autoantibody-negative relatives (98.6%). Capillary blood sampling was perceived as more painful than venous blood draw, but 60% of participants would prefer initial screening using home fingerstick with clinic visits only required if autoantibodies were found.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Capillary blood sampling could facilitate screening for type 1 diabetes prevention studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/dia.2015.0133","type":"journal-article","created":{"date-parts":[[2015,9,16]],"date-time":"2015-09-16T16:40:50Z","timestamp":1442421650000},"page":"867-871","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":23,"title":["Use of Dried Capillary Blood Sampling for Islet Autoantibody Screening in Relatives: A Feasibility Study"],"prefix":"10.1177","volume":"17","author":[{"given":"Polly J.","family":"Bingley","sequence":"first","affiliation":[{"name":"University of Bristol","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa E.","family":"Rafkin","sequence":"additional","affiliation":[{"name":"University of Miami"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Della","family":"Matheson","sequence":"additional","affiliation":[{"name":"University of Miami"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea K.","family":"Steck","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Yu","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Henderson","sequence":"additional","affiliation":[{"name":"University of South Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Beam","sequence":"additional","affiliation":[{"name":"University of Western Michigan Homer Stryker MD School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Boulware","sequence":"additional","affiliation":[{"name":"University of South Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the TrialNet Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,12,1]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2004.01142.x"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.2.275"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.6.874b"},{"key":"e_1_3_3_5_2","first-page":"855","article-title":"A simple screening method for individuals at risk of developing type 1 diabetes: measurement of islet cell autoantibodies (GADA, IA-2A, and IAA) on dried capillary blood spots collected on a filter paper","volume":"44","author":"Siraj ES","year":"2013","unstructured":"Siraj ES, , Rogers DG, , Gupta MK, et al.: A simple screening method for individuals at risk of developing type 1 diabetes: measurement of islet cell autoantibodies (GADA, IA-2A, and IAA) on dried capillary blood spots collected on a filter paper. Horm Metab Res, 2013; 44:855\u2013860.","journal-title":"Horm Metab Res"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5448.2008.00464.x"},{"key":"e_1_3_3_7_2","unstructured":"Type 1 Diabetes-TrialNet Study Group: Natural History Study of the Development of Type 1 Diabetes (Protocol TN-01). https:\/\/www.diabetestrialnet.org\/documents\/ancillary\/PTPProtocolSynopsis&SpecimenCollectionSchedule_ProtocolV15Aug11.pdf (accessed April13 2015)."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0293"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-2081"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2583-4"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0643"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/dia.2015.0133","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2015.0133","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2015.0133","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:15:53Z","timestamp":1777400153000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/dia.2015.0133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1089\/dia.2015.0133"],"URL":"https:\/\/doi.org\/10.1089\/dia.2015.0133","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}